STAT Degrader

PROTAC STAT6 degrader-10 is a bifunctional STAT6 degrader with a DC₅₀ value of >1 μM. PROTAC STAT6 degrader-10 recruits STAT6 protein to E3 ubiquitin ligase for ubiquitination and subsequent degradation. PROTAC STAT6 degrader-10 can be used for the research of inflammatory disorders, allergies, asthma, eczema.

PROTAC STAT6 degrader-4 (Compound 3u247) is a STAT6 PROTAC degrader with a DC₅₀ of 0.04 nM. PROTAC STAT6 degrader-4 promotes the ubiquitination and degradation of STAT6, and is applicable to the research of immune diseases.

PROTAC STAT3 degrader-2 is a PROTAC degrader that targets STAT3, with a DC₅₀ value of 3.54 μM. PROTAC STAT3 degrader-2 inhibits the growth of leukemia and lymphoma cells with high levels of phosphorylated STAT3. PROTAC STAT3 degrader-2 is used in the research of acute myeloid leukemia and anaplastic large cell lymphoma.

S3D5 is a highly efficient and selective PROTAC degrader targeting STAT3 (KD = 4.35 μM). S3D5 induces degradation of STAT3 in HepG2 cells without significant effects on other STAT proteins. S3D5 exhibits good anti-hepatocellular carcinoma cell proliferation activity, which can be explained by activating the p53 pathway. S3D5 degradation of the STAT3 protein is mediated by the ubiquitin–proteasome system (UPS). S3D5 can be used for the study of hepatocellular carcinoma.

STAT3 degrader-1 is a small-molecule targeted protein degrader that targets STAT3. STAT3 degrader-1 is applicable to studies on STAT3-dependent signaling pathways and leukemia.

KT-333 (Standard) is the analytical standard of KT-333 (HY-156730). This product is intended for research and analytical applications. KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL).